Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736506 | 0.88 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HTR6MBTD1MEN1 | |
| SCHEMBL735454 | 0.86 | SLC18A3 (0.37) | L3MBTL3L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL2003992 | 0.86 | SLC18A3 (0.37) | L3MBTL3L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL735446 | 0.86 | SLC18A3 (0.35) | L3MBTL3L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL736728 | 0.84 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HTR6MBTD1SLC18A3 | |
| SCHEMBL738220 | 0.84 | SLC18A3 (0.38) | MEN1KMT2ASLC18A3 | |
| SCHEMBL2006246 | 0.84 | SLC18A3 (0.38) | MEN1KMT2ASLC18A3 | |
| SCHEMBL736888 | 0.81 | — | — | |
| SCHEMBL736159 | 0.81 | — | — | |
| SCHEMBL736079 | 0.80 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1HTR6MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347541-A2 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024062043-A1 | SUBSTITUTED PHENOTHIAZINES AS FERROPTOSIS INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024059119-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | SOLIOME, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240059688-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2024-02-22 | — | — | US | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-9750745-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-09-05 | — | — | US | disclosed |
| US-20170157137-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9617264-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-04-11 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119782-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| US-20170015665-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2017-01-19 | — | — | US | disclosed |
| WO-2016083490-A1 | COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES | REMYND NV (BE) | 2016-06-02 | — | — | WO | disclosed |
| WO-2015140132-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | L3MBTL3 2736/4885L3MBTL1 2074/4885HTR6 4586/4885 |
| US-20170157137-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | PSEN1, MAPT, PSEN2 | L3MBTL3 176/4885L3MBTL1 51/4885HTR6 3559/4885 |
| US-20170015665-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | PSEN1, MAPT, PSEN2 | L3MBTL3 176/4885L3MBTL1 51/4885HTR6 3559/4885 |
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | KLK3, FOLH1, CA14 | L3MBTL3 4041/4885L3MBTL1 3756/4885HTR6 3209/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | L3MBTL3 60/4885L3MBTL1 37/4885HTR6 3596/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | L3MBTL3 577/4885L3MBTL1 494/4885HTR6 4266/4885 |
| US-20240059688-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER | ACKR3, CMKLR1, CXCR4 | L3MBTL3 291/4885L3MBTL1 532/4885HTR6 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.